The effect of curcumin and vitamin D s on headache symptoms and inflammation in patients with migraine

The effect of concurrent curcumin and vitamin D supplementation on headache symptoms and calcitonin gene-related peptide level (CGRP) in patients with migraine

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20170929036477N4

Enrollment

Registered

2021-08-10

Start date

2021-08-28

Completion date

Unknown

Last updated

2021-08-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Migraine. Migraine without aura [common migraine]

Interventions

Intervention 1: "Intervention group": migraine patients intake curcumin supplement in the form of 500 mg capsules from Karen Company, one per day with routine treatment (200 mg sodium valproate tablet

Eligibility

Sex/Gender

All

Age

20 Years to 50 Years

Inclusion criteria

Inclusion criteria: Willingness to cooperate with the plan Diagnosis of migraine by a neurologist based on ICHD-3 criteria. Age 20 to 50 years. No chronic diseases (liver, kidney, cardiovascular disease, secondary headache or other types of primary headache except migraine) Absence during pregnancy and lactation No taking dietary supplements or medication (nutritional supplements, multivitamin mineral and W3 supplements or anti-migraine medications (valproate, amitriptyline, etc.), anti-inflammatory and anti-depressant pills, Aspirin and NSAIDs, contraceptives in the last three months Failure to follow a specific diet or exercise program during the last three months

Exclusion criteria

Exclusion criteria: alcohol and smoking

Design outcomes

Primary

Measure	Time frame
Severity of migraine. Timepoint: Before the intervention and at the end of the study. Method of measurement: Visual Analogue Scale.;Migraine frequency. Timepoint: Before the intervention and at the end of the study. Method of measurement: Question / Number of attacks per month.;Duration of migraine headache. Timepoint: Before the intervention and at the end of the study. Method of measurement: Question / Number of attacks per month.;The degree of disability caused by migraines. Timepoint: Before the intervention and at the end of the study. Method of measurement: Headache Impact Test Questionnaire.;Calcitonin gene-related peptide. Timepoint: Before the intervention and at the end of the study. Method of measurement: blood test.	—

Measure

Time frame

Severity of migraine. Timepoint: Before the intervention and at the end of the study. Method of measurement: Visual Analogue Scale.;Migraine frequency. Timepoint: Before the intervention and at the end of the study. Method of measurement: Question / Number of attacks per month.;Duration of migraine headache. Timepoint: Before the intervention and at the end of the study. Method of measurement: Question / Number of attacks per month.;The degree of disability caused by migraines. Timepoint: Before the intervention and at the end of the study. Method of measurement: Headache Impact Test Questionnaire.;Calcitonin gene-related peptide. Timepoint: Before the intervention and at the end of the study. Method of measurement: blood test.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSiavash Fazelian

Shahre-kord University of Medical Sciences

Siavashfazelian@yahoo.com+98 912 839 0366

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026